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Abstract
Background: Acute coronary syndromes (ACS) are complex and polygenic diseases which are a real problem of
public health. These syndromes require multidisciplinary studies to understand the pathogenesis mechanisms.
Our study aims to evaluate the endothelin-1 (ET-1) serum concentration in Tunisian coronary compared to controls
healthy, as well as the study of the impact of an intronic polymorphism A (8002) G of pre-pro-endothelin-1 Gene
(inactive precursor of ET-1) on the change in serum endothelin-1 and in the susceptibility to Acute coronary
syndrome (SCA).
Methods: Our samples were subdivided into coronary patients (157) and healthy subjects (142). The quantification
of the ET-1 concentration was performed by high performance liquid chromatography, the identification of the
different genotypes of the polymorphism A(8002)G was made by PCR-RFLP. The association between the ET-1
concentration and identified genotypes was realized by adapted software for descriptive statistics, Statistical Package
for the Sociological Sciences (SPSS v 21.0).
Results: Our study showed that the concentration of ET-1 was significantly higher in patients compared to
controls and that the mutated allele prevails in patients F (G) = 0.78 and there is a minority in controls F (G) = 0.3.
Secondly the homozygous genotype GG is associated with higher concentrations of ET-1 in patients and controls,
heterozygous genotype AG is associated with intermediaries’ values and AA genotype is related to lower values.
Conclusion: Although the polymorphism studied is an intronic polymorphism, it is involved in the change in serum
concentration of ET-1 and is a candidate gene in susceptibility to SCA. Cardiovascular diseases are “polygenic”
pathology and do not obey of the law for transmission of Mendel.
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Background
Endothelin-1 (ET-1) is an endothelium derived, potent
vasoconstrictor peptide of 21 amino acids (2.5 kDa with a
great structural homology with snake venom, the S6 sara-
fotoxin). It was isolated and sequenced from endothelial
cell culture by Yanagisawa in 1988. Its peptide is strongly
implicated in the coronary artery diseases genesis and
complications by its vasoconstrictors effects [1–3].
This peptide is synthesized as a precursor inactive for
212 amino acids (pre-pro-endothelin-1) then undergoes an
enzymatic activation cascade to give mature endothelin-1
of 21 amino acids [3–5].
At the molecular level, Pre-pro-endothelin-1 is expressed
by a gene with 9 kb located in chromosome 6 (6p24.1) and
composed of 5 exons and 4 introns [6, 7].
In this context, the aim of our study was to quantify the
serum concentrations of ET-1 among Tunisian coronary
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patients compared to healthy controls, and study the im-
pact of an intronic polymorphism A (8002) G (intron 4) of
the pre-pro-endothéline-1 gene in the serum concentra-
tion of ET-1 and the susceptibility to coronary syndromes.
Methods
Populations study
This is a retrospective case-control study, in which, sam-
pling was carried between January 2010 and November
2011. One hundred fifty seven Tunisian coronary subjects
(121 men and 36 women) middle-aged (64.8 ± 11.7 years),
chosen according to the clinical data, essentially electro-
cardiogram. One hundred forty two healthy subjects (111
men and 31 women) middle-aged (56.8 ± 9.4 years), with-
out heart disease or other and they are a lot less exposed
to cardiovascular risk factors and are not under any treat-
ment, were considered as the healthy group.
The patients and healthy subjects signed a free and clear
consent which explain the objectives of this work with an
undertaking not to publish the names of participants, their
personal data including test results (following the instruc-
tions of the Tunisian Medical Ethics Committee, consist-
ent with the Helsinki Declaration).
The approval of compliance with the Helsinki declar-
ation was signed in December 2009 by Mrs the Dean of
Faculty of Pharmacy of Monastir, Tunisia, as a member of
the Tunisian Medical Ethics Committee.
A datasheet had been prepared for each subject (patient
or control) to identify cardiovascular risk factors and
know the susceptibility degrees to ACS. This sheet con-
tains the anthropometric characteristics, the biological
parameters, the risk factors, the treatments of patients,
inclusion criteria (unstable angina and myocardial infarc-
tion), exclusion criteria (cancer, thyroid diseases).
Laboratory analysis
A collection of three tubes were made for each patient
and control: one tube without anticoagulant for ET-1 con-
centration, lipid profile and apolipoprotein the second one
is EDTA tube for genomic analysis and the third with
Heparin Lithium for glycemia.
A simple biochemical investigation (blood glucose, lipid
profile) was done by colorimetric essay (Randox-Antrim,
UK) and apolipoprotein measurements by an immunone-
phelemetry essay (Cobas Integra 400, Roche) to explore
the risk of exposure to acute Coronary syndrome in
patients and witnesses.
After plasmatic ET-1 extraction with ethanol, the
concentration was measured by High Performance Chro-
matography, coupled to Mass Spectrometry (3200 Q
TRAP LC/MS/MS system), according to the Walczak M
protocol, 2010 [8], using a synthetic standard (ET-1
Sigma-Aldrich St. Louis, MO, USA) for the specific
spectra identification and for the calibration curve
determining. Chromatographic separation was carried out
with C18 analytical column (30 mm × 2.1 mm, 3.5 μm,
Waters Ireland) set at 20 °C. Two solvents mixtures were
used: solvent A: Acetonitrile and solvent B: H2O. The
following gradient was used: 0-5 min 0-100 % A; 5–7 min
100 % A; 7–8, 100–0 % A; 8–15 min, 100 % B. The flow
rate was set at 300 μL.min−1 and a sample volume of 25 μl
was injected in the analytical column.
Genomic DNA was isolated from peripheral leukocytes
by a standard technique using Phenol-Chloroform and
Proteinase K. The G(8002)A polymorphism in intron 4 in
pre-pro-endothelin-1 gene was detected according to our
protocol RFLP-PCR product (primers 5’-CAA ACC GAT
GTC CTC TGT A-3’ and 5’-ACC AAA CAC ATT TCC
CTA TT-3’). The PCR reaction was performed in a total
volume of 25 μL containing 3 μl 10 × PCR buffer, 3 mM
MgCl2, 0.2 mmol/L dNTPs, 0.25 μmol/L each primer,
150 ng of genomic DNA and 1 U of Taq DNA polymerase
(Promega). The PCR conditions were 95 °C for 90 s,
followed by 35 cycles of 30 s at 95 °C, 45 s at 56 °C and
30 s at 72 °C, with a final elongation at 72 °C for 7 min.
The PCR product was digested by restriction analysis
with Taq I (T↓CGA) on electrophoresis gel with ethidium
bromide. Three genotypes GG, 150 and 208 bp, GA, 358,
150, and 208 bp, and AA, 358 bp were identified.
Statistical analysis
Database management and statistical analyses were carried
out using SPSS (Statistical Package for the Sociological
Sciences), version 21.0. Results are presented as means ±
SD, or percentages. Means were compared using Student
test. The significance threshold was set at 5 % (p < 0.05).
The impact of the mutated alleles and genotypes was iden-
tified by a Chui square test.
Our study escapes from Hardy-Weinberg model for
two major reasons:
The first is that our sampling is a selective sampling
(patients with genetic risk factor and healthy controls
unexposed to genetic cardiovascular factors). The second
is the dominance of the consanguinity (union between
first cousins) in the Tunisian population.
Results
Clinical characteristics and biochemical parameters of pa-
tients with coronary artery syndrome and control groups
are illustrated in Table 1. No significant difference was
observed between the 2 groups in the basis of mean
of age and sex. Among cardiovascular risk factors, dia-
betes, hypertension, smoking and dyslipidemia are greatly
mentioned in patients compared with healthy subjects.
The disorder of apolipoproteins was observed in patients,
there was a significant increase in Apo B serum level and
a decreased in serum Apo A-1 level compared with serum
apolipoprotein levels in healthy subjects.
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On the other hand, the ET-1 concentration was signifi-
cantly higher in patients compared to healthy subjects.
Table 2 shows the variation of the serum concentration of
ET-1 in healthy subjects and in patients according to car-
diovascular risk factors. This investigation has shown that
this vasoconstrictor depends on gender, arterial hyperten-
sion, tobacco, obesity and dyslipidemia, unlike diabetes,
alcohol and physical inactivity.
Our molecular study shows that the mutated allele G
prevails in patients with a frequency F (G) = 0.78 and the
non-mutated allele A is majority in control group with a
frequency F (A) = 0.65 (Table 3). The identification of
genotypes (by RFLP- PCR) is illustrated in Fig. 1.
Independence Chi-square test proves that the GG geno-
type is associated with ACS, χ2 = 58.75 > > 3.841 (degree
of liberty = 1 and α =3.841).
The same test proves the implication of G allele in
the disease, χ2 = 60.69 > > 5.999 (degree of liberty = 2
and α = 5.999).
The different genotypes distribution between patients
and healthy group, and the association between geno-
types and serum level of ET-1 are shown in Table 3,
Figs. 2 and 3 respectively.
This association showed that the mutated homozygous
genotype is associated with higher serum values of ET-1,
that the non-mutated homozygous genotype is associated
with lowest values and heterozygous, while AG genotype
is linked to intermediate values, this observation is valid
for patients and healthy group.
Discussion
Varied risk factors among patients confirm the multifac-
torial and polygenic origin of the ACS, well explained by
the Framingham study. The lipid profile of patients was
partially balanced because the required diet and hypolipid-
emic treatment, essentially the angiotensin-1 converting







Age (x ± σ years) 64.8 ± 11.7 56.8 ± 9.4 NS
Sex . Men (%) 121 (77 %) 111 (78.2 %) NS
Women (%) 36 (23 %) 31 (21.8 %) NS
BMI (kg/m2) 27.6 ± 4 23.3 ± 2.2 NS
Hypertension (%) 88 0 -
Obesity (%) 52 8.5 % -
Diabetes (%) 64 0 -
Smoking (%) 62.4 7 -
Family cardiac history (%) 68 6 -
Personnel cardiac history (%) 66 0 -
Postmenopausal women (%) 100 82 -
Dyslipidemia (%) 40 0 -
Sedentary (%) 43 11 -
Alcohol (%) 33 14 -
Glucose (x ± σ mmolL/) 9.8 ± 4.2 5.40 ± 0.84 <0.0001
TC (x ± σ mmol/L) 5.70 ± 3.1 4.60 ± 2.6 <0.001
HDL-C (x ± σ mmol/L) 1.14 ± 0.22 1.30 ± 0.41 NS
LDL-C (x ± σ mmol/L) 3.60 ± 2.16 2.80 ± 1.4 <0.001
TG (x ± σ mmol/L) 1.60 ± 0.9 1.24 ± 0.3 NS
ApoA1 (x ± σ. g/L) 1.41 ± 0.62 1.80 ± 0.2 <0.00001
ApoB (x ± σ. g/L) 1.40 ± 0.81 0.70 ± 0.2 <0.00001
Treatment: ACA-1 inhibitors (%) 97 0 -
Statins (%) 38 0 -
Beta-Blockers (%) 33 0 -
Ca-Blockers (%) 27 0 -
Diuretics (%) 17 0 -
Table 2 The variation of the ET-1 concentration among patients
according risk factors
Populations and risk factors ET-1 (nmol/L) P
Population Patients (n = 157) 15.2 ± 5.3 <0.00001
Controls (n = 142) 7.1 ± 2.7
Gender Men (n = 121) 17.4 ± 4.6 <0.00001
Women (n = 36) 7.8 ± 2.3
Hypertension Yes (n = 138) 16.4 ± 3.3 <0.00001
No (n = 19) 6.6 ± 1.9
Diabetes Yes (n = 101) 15 ± 5.1 NS
No (n = 56) 15.6 ± 3.8
Tobacco Yes (n = 98) 11.6 ± 3 <0.00001
No (n = 59) 21.2 ± 6.1
Obesity Yes (n = 82) 12.2 ± 5.3 <0.001
No (n = 75) 18.2 ± 4
Dyslipidemia Yes (n = 63) 11.8 ± 1.6 <0.00001
No (n = 94) 17 .5 ± 4.6
Alcohol Yes (n = 52) 16 ± 4.1 NS
No (n = 105) 14.8 ± 3.8
Sedentarity Yes (n = 67) 15.7 ± 3.7 NS
No (n = 90) 14.9 ± 2.4
Table 3 Genotypes (associated with the ET-1 serum level) distri-
bution among patients and controls
Allele frequencies Genotypes ET-1 (nmol/L) P
Patients (157) F(A) = 0.22 AA (12 %) 10.38 ± 4.6 a NS
F(G) = 0.78 AG (20 %) 12.33 ± 3.1 b 0.001
GG (68 %) 16.9 ± 4.2 c 0.001
Controls (142) F(A) = 0.65 AA (54 %) 5.61 ± 1.3 a 0.001
F(G) = 0.35 AG (22.5 %) 7.27 ± 1.2 b 0.001
GG (23.5 %) 9.3 ± 2.8 c 0.001
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enzyme inhibitors with its beneficial effects against meta-
bolic syndrome and lipid complications [9, 10].
The increased concentrations of apolipoprotein B
(although 38 % of patients are under statins) consolidate
its atherogenic effects and its involvement in the ACS
genesis, whereas Apo A1 (is statistically higher in con-
trols) has a cardio-protective effect supported by various
studies [11–13].
Our study shows a statistically significant increase in
the ET-1 values among patients compared to control sub-
jects (although 33 % of patients are under Beta-Blockers
and 27 % are under Ca-Blockers generally used, in this
advanced stage of coronary syndrome for reduce the
mortality of coronary, particular which have a myocardial
infarction), which reflects its role not only in a prolonged
vasoconstriction but also in its atherogenic impact, its
pro-oxidant effect (indirectly involved in the NADPH
oxidase activation and radical oxygen species generation)
and its pro-aggregating effect (by its role in the thromb-
oxane A2 synthesis) [5, 14, 15].
The ET-1 level depends, in this study on gender, hyper-
tension, smoking, obesity and dyslipidemia, unlike dia-
betes, alcohol and physical inactivity.
The high concentration of ET-1 among men patients
compared to women patients shows the effect of the male
gender as an un-modifiable cardiovascular risk factor.
This increase of ET-1 level has a metabolic origin and
non-genetic, since our peptide is expressed by an auto-
somal gene and the same actors and cleavage and matur-
ation enzymes (endothelin-1 converting enzyme…) are
also derived from autosomal genes [8, 16, 17].
The elevated concentration of ET-1 among hyperten-
sive patients compared with normotensive patients is
explained by the vasoconstrictor effect of ET-1 and its
Fig. 1 Genotypes identification by RFLP-PCR (on 2 % agarose gel): a before enzymatic digestion, single band, with 358 bp corresponding to “intact
intron 4”, b post enzymatic digestion of PCR products, with the different genotypes (AA with 358 bp, AG with 358 bp + 208 bp + 150 bp and GG
with 208 bp and 150 bp). M: molecular weight ladder (100 bp); pb: base pairs; PFLP-PCR: restriction fragment length polymorphism-Polymerase
Chain Reaction
Fig. 2 The serum concentration of ET-1 according to different genotypes among control group
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roles in the sodium reabsorption, in hyperactivity these
regulatory effects become hypertensive [17–19].
The ET-1 concentration was inhibited by smoking, obes-
ity and dyslipidemia, this inhibition is explained in the
literature by the roles of these factors in the genesis and
complications of metabolic syndrome. This latter, generates
a liver impuissance in degradation and neutralization of
cytotoxic elements that infect the endothelium, main
secretory tissue of ET-1.
Otherwise, nicotine has a harmful effect on the endothe-
lium and prevents secretion of endothelial factors [20–22].
The dominance of the mutated allele G in patients
proves the effect of this allele as a genetic component to
susceptibility to acute coronary syndrome. This dominance
has resulted in a majority of patients with homozygous
genotype GG (highly exposed to risk) and heterozygous
AG patients intermediately exposed (single dose exposure
from for patients with AG and double dose exposure for
patients with GG).
For the minority of patients non-carriers of the mu-
tated allele (12 %), we can confirm that the provenance
of disease is linked to other factors (which again proves
the diverse origin and polygenic nature of ACS).
For healthy group, the majority carries the non-mutated
genotype AA, the presence of healthy subjects AG or GG
proves the non Mendelian nature of this polymorphism.
The G allele among controls can be called “silent risk
marker or candidate allele currently» neutral” [23–26].
The association between G allele and coronary risk is
explained by the association between the G allele and high
level of ET-1 in patients and healthy subjects (Figs. 2 and
3). The GG genotype is associated with elevated values of
ET-1 in patients and controls, while the AG genotype is
associated with intermediate values in both populations
and AA genotype is associated with the lowest values.
Although this polymorphism is an intronic polymorphism
(it does not affect the final structure of the protein) its
functionality is caused by the role of introns in the regula-
tion of the protein expression level (they fix the transcrip-
tion factors), an intronic aberration may amplify or inhibit
the level of protein expression [5, 27].
Conclusion
ACS is a complex disease that does not obey of the Men-
del transmission law, the pathophysiology is caused by an
overlap between genetic and behavioral factors (smoking,
physical inactivity …). A good understanding of coronary
pathophysiology requires multidisciplinary studies of risk
factors and candidate genes, their degree of involvement
and linkage disequilibrium between them.
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